PLx Pharma Inc. (PLXP) and Acceleron Pharma Inc. (NASDAQ:XLRN) Comparison side by side

PLx Pharma Inc. (NASDAQ:PLXP) and Acceleron Pharma Inc. (NASDAQ:XLRN) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PLx Pharma Inc. N/A 68.66 N/A -1.14 0.00
Acceleron Pharma Inc. 13.99M 174.12 118.87M -2.45 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of PLx Pharma Inc. and Acceleron Pharma Inc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
PLx Pharma Inc. 0.00% -162.4% -40.7%
Acceleron Pharma Inc. -849.68% -36.6% -34.6%

Risk & Volatility

PLx Pharma Inc.’s volatility measures that it’s 433.00% more volatile than S&P 500 due to its 5.33 beta. Acceleron Pharma Inc. on the other hand, has 1.41 beta which makes it 41.00% more volatile compared to S&P 500.

Liquidity

4.8 and 4.8 are the respective Current Ratio and a Quick Ratio of PLx Pharma Inc. Its rival Acceleron Pharma Inc.’s Current and Quick Ratios are 16.2 and 16.2 respectively. Acceleron Pharma Inc. has a better chance of clearing its pay short and long-term debts than PLx Pharma Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for PLx Pharma Inc. and Acceleron Pharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PLx Pharma Inc. 0 0 0 0.00
Acceleron Pharma Inc. 0 0 3 3.00

Acceleron Pharma Inc. on the other hand boasts of a $73.33 consensus price target and a 55.59% potential upside.

Insider & Institutional Ownership

Institutional investors owned 24.3% of PLx Pharma Inc. shares and 87.4% of Acceleron Pharma Inc. shares. Insiders owned roughly 5.73% of PLx Pharma Inc.’s shares. Comparatively, insiders own roughly 14.2% of Acceleron Pharma Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PLx Pharma Inc. 4.08% -8.93% 23.79% 54.55% -25% 233.33%
Acceleron Pharma Inc. 9.34% 9.06% -13.57% -13.2% 13.86% 6.18%

For the past year PLx Pharma Inc.’s stock price has bigger growth than Acceleron Pharma Inc.

Summary

Acceleron Pharma Inc. beats PLx Pharma Inc. on 6 of the 10 factors.

PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. Its lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. The companyÂ’s product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development. The company was founded in 2002 and is headquartered in Houston, Texas.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.